Clinical Trial

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Protocol Amendment History 4 changes
notable Trial sites expanded: 115 -> 118 locations 2026-07-07
notable Trial sites expanded: 108 -> 113 locations 2026-05-09
notable Trial sites expanded: 103 -> 108 locations 2026-04-14
minor Completion pushed: 2028-07-11 -> 2029-06-18 2026-04-14
Trial Details
NCT Number NCT05327114
Lead Sponsor Janssen Research & Development, LLC
Conditions Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Enrollment 201 participants
Start Date 2022-09-23
Primary Completion 2027-05-14 (estimated)
Study Completion 2029-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-06